ClinicalTrials.gg
CompletedNCT05425732Updated Oct 26, 2024Results posted

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

A Phase 3 interventional study of V116 and PCV20 in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 112 sites in 11 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,663
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
Largest of 10
2,663 · median 1,075
Started
2022
with 3 others
Phase 3
9 of 10
1 open now
Registered
3rd of 10
by date
Lead sponsor
8 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one has the largest enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 3rd registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Pneumococcal 21-Valent Conjugate Vaccine

Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine ([Prevnar 20™ / APEXXNAR™]) in pneumococcal vaccine-naïve adults. It is hypothesized that V116 is noninferior to PCV20 for the common serotypes and superior to PCV20 for the unique serotypes as assessed by serotype specific opsonophagocytic activity (OPA) 30 days postvaccination. It is also hypothesized that V116 in participants 18 to 49 years of age immunobridges to V116 in participants 50 to 64 years of age as assessed by serotype specific OPA geometric mean titers (GMTs) 30 days postvaccination for all 21 serotypes in V116. Participants ≥50 years of age will be enrolled in Cohort 1, and participants 18 to 49 years of age will be enrolled in Cohort 2.

03

Conditions studied

  • Pneumococcal Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For females, is not pregnant or breastfeeding and is either not a woman of (WOCBP) or is a WOCBP and uses acceptable /abstinence; and has medical, menstrual, and recent sexual activity history reviewed by the investigator to decrease the chance of an early undetected pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Has a history of invasive pneumococcal disease (IPD) [positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site] or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1)
  • Has a known to any component of V116 or PCV20, including diphtheria toxoid
  • Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented (HIV) infection, functional or anatomic asplenia, or history of disease
  • Has a coagulation disorder contraindicating IM vaccination
  • Had a recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring \<72 hours before receipt of study vaccine
  • Has a known that is progressing or has required active treatment \<3 years before enrollment
  • Received prior administration (prior to age of 5 is acceptable) of any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol
  • Received systemic (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention ≥14 days before receipt of study vaccine
  • Is currently receiving therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
  • Received any nonlive vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤30 days after receipt of study vaccine (inactivated influenza and SARS-CoV2 vaccines may be acceptable)
  • Received any ≤30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine
  • Received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,663 participants (actual)

Study arms

  • Experimental
    Cohort 1 V116

    Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of V116 on Day 1.

    Biological: V116

  • Active comparator
    Cohort 1 PCV20

    Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of PCV20 on Day 1.

    Biological: PCV20

  • Experimental
    Cohort 2 V116

    Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of V116 on Day 1.

    Biological: V116

  • Active comparator
    Cohort 2 PCV20

    Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of PCV20 on Day 1.

    Biological: PCV20

Interventions

  • BiologicalV116

    0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.

    Also known as: Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPCV20

    0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.

    Also known as: Prevnar 20™, APEXXNAR™

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.

    Time frame: Up to 5 days post-vaccination

  2. Percentage of Participants With Solicited Systemic AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C)

    Time frame: Up to 5 days post-vaccination

  3. Percentage of Participants With Vaccine-related Serious AE (SAE)

    A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event, which is determined by the investigator to be related to the vaccine.

    Time frame: Up to 194 days post-vaccination

  4. Serotype Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20

    The serotype specific OPA GMTs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using the multiplex opsonophagocytic assay (MOPA). GMT values were estimated from a constrained longitudinal data analysis; (cLDA) model. Per protocol, within group, confidence intervals (CIs) or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

    Time frame: Day 30 post-vaccination

  5. Percentage of Participants With ≥4-fold Change From Baseline in Serotype Specific OPA Responses in Cohort 1 Only for the 11 Unique Pneumococcal Serotypes Contained in V116

    The percentage of participants with ≥4-fold rise from baseline in serotype specific OPAs for the 11 unique pneumococcal serotypes contained in V116. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

    Time frame: Baseline and Day 30 post-vaccination

  6. Serotype Specific OPA GMTs in Participants 18-49 Years and Participants 50-64 Years for the Pneumococcal Serotypes Contained in V116

    The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA. GMT values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.

    Time frame: Day 30 post-vaccination

Secondary outcomes

  1. Percentage of Participants From Cohort 1 V116 With ≥4-fold Change in OPA Responses for Cross Reactive Pneumococcal Serotypes

    The percentage of participants with ≥4-fold rise from baseline was determined for Cohort 1 V116 serotypes 6C and 15B, two serotypes which cross react with PCV20. Point estimate and 95% CI are based on the Clopper-Pearson method. A conclusion of acceptability is based on the lower bound of the 95% CI of the percentages of participants with a ≥4-fold rise from baseline being \> 50 percentage points (one-sided p-value \< 0.025). Per protocol, participants treated with PCV20, and V116 Cohort 2 were not analyzed in this outcome measure.

    Time frame: Baseline and Day 30 post-vaccination

  2. Serotype Specific OPA GMTs for Cross Reactive Pneumococcal Serotypes in Adults 50 to 64 Years of Age From Cohort 1 and Adults 18 to 49 Years of Age From Cohort 2

    The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA for serotypes 6C and 15B which cross react with PCV20. GMT values were estimated from a LDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.

    Time frame: Day 30 post-vaccination

  3. Serotype Specific Immunoglobulin (IgG) Geometric Mean Concentrations (GMCs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20

    The serotype specific IgG GMCs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using pneumococcal electrochemiluminescence (PnECL). GMC values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

    Time frame: Day 30 post-vaccination

  4. Geometric Mean Fold Change From Baseline in OPA GMTs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20

    The geometric mean fold rise (GMFR) from baseline in serotype specific OPA GMTs for cohort 1 was determined using MOPA. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

    Time frame: Baseline and Day 30 post-vaccination

  5. Geometric Mean Fold Change From Baseline in IgG Antibody GMCs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20

    The GMFR from baseline in serotype specific IgG antibody GMCs for cohort 1 was determined using PnECL. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

    Time frame: Baseline and Day 30 post-vaccination

  6. Percentage of Participants With ≥4-fold Change From Baseline in IgG Antibody GMCs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20

    Percentage of participants with ≥4-fold rise from baseline in serotype specific IgG antibody GMCs for cohort 1 was determined using PnECL. The within-group 95% CIs were based on the exact binomial method proposed by Clopper and Pearson. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

    Time frame: Baseline and Day 30 post-vaccination

  7. Percentage of Participants With ≥4-fold Change From Baseline in OPA GMTs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20

    Percentage of participants with ≥4-fold rise from baseline in OPA GMTs in Cohort 1 was determined using MOPA. The within-group 95% CIs were based on the exact binomial method proposed by Clopper and Pearson. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

    Time frame: Baseline and Day 30 post-vaccination

07

Results

Posted Jun 10, 2024

Participant flow

Pneumococcal vaccine-naïve adults ≥18 years of age were enrolled in this study. Participants with underlying chronic conditions were eligible if the conditions were assessed to be stable per the investigator's judgment.

Participant flow — Overall Study
MilestoneCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Started11811181201100
Vaccinated11791177200100
Safety all cause mortality (acm) population11791179201100
All participants as treated (apat)11771175200100
Safety adverse event (ae) population11771175200100
Completed1160115219596
Not completed212964
Withdrew: Death4200
Withdrew: Lost to follow-up101553
Withdrew: Physician decision0200
Withdrew: Randomized by mistake without study treatment1200
Withdrew: Withdrawal by subject4811
Withdrew: Randomized to pcv20 first, discontinued; then randomized to v116 second2000

Outcome measures

PrimaryPercentage of Participants With Solicited Injection-site Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
Percentage of participantsCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Injection site erythema5.46.315.513.0
Injection site pain39.451.771.574.0
Injection site swelling6.08.314.014.0
Statistical analysis
  • Cohort 1 V116 vs Cohort 1 PCV20 · Difference in percent: -0.9 · 96% CI -2.8 to 1.1V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Difference in percent: -12.2 · 95% CI -16.2 to -8.2V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Difference in percent: -2.3 · 95% CI -4.4 to -0.2V116 minus PCV20
  • Cohort 2 V116 vs Cohort 2 PCV20 · Difference in percent: 2.5 · 95% CI -6.6 to 10.3V116 minus PCV20
  • Cohort 2 V116 vs Cohort 2 PCV20 · Difference in percent: -2.5 · 95% CI -12.7 to 8.6V116 minus PCV20
  • Cohort 2 V116 vs Cohort 2 PCV20 · Difference in percent: 0.0 · 95% CI -9.2 to 7.9V116 minus PCV20
PrimaryPercentage of Participants With Solicited Systemic AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C)

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Systemic AEs
Percentage of participantsCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Fatigue20.119.640.534.0
Headache11.512.929.524.0
Myalgia5.96.716.514.0
Pyrexia1.31.33.51.0
Statistical analysis
  • Cohort 1 V116 vs Cohort 1 PCV20 · Difference in percent: 0.6 · 95% CI -2.7 to 3.8V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Difference in percent: -1.5 · 95% CI -4.1 to 1.2V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Difference in percent: -0.8 · 96% CI -2.8 to 1.2V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Difference in percent: -0.0 · 95% CI -1.0 to 1.0V116 minus PCV20
  • Cohort 2 V116 vs Cohort 2 PCV20 · Difference in percent: 6.5 · 95% CI -5.3 to 17.6V116 minus PCV20
  • Cohort 2 V116 vs Cohort 2 PCV20 · Difference in percent: 5.5 · 05% CI -5.5 to 15.5V116 minus PCV20
  • Cohort 2 V116 vs Cohort 2 PCV20 · Difference in percent: 2.5 · 95% CI -6.8 to 10.6V116 minus PCV20
  • Cohort 2 V116 vs Cohort 2 PCV20 · Difference in percent: 2.5 · 95% CI -2.2 to 6.2V116 minus PCV20
PrimaryPercentage of Participants With Vaccine-related Serious AE (SAE)

A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event, which is determined by the investigator to be related to the vaccine.

Time frame:
Up to 194 days post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Vaccine-related Serious AE (SAE)
Percentage of participantsCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Percentage of Participants With Vaccine-related Serious AE (SAE)0.00.00.00.0
PrimarySerotype Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20

The serotype specific OPA GMTs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using the multiplex opsonophagocytic assay (MOPA). GMT values were estimated from a constrained longitudinal data analysis; (cLDA) model. Per protocol, within group, confidence intervals (CIs) or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Time frame:
Day 30 post-vaccination
Reported as:
Geometric mean · Titer
Serotype Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20
TiterCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Serotype 3274.0 (NA to NA)176.7 (NA to NA)——
Serotype 6A2302.0 (NA to NA)2972.5 (NA to NA)——
Serotype 7F3637.4 (NA to NA)3429.9 (NA to NA)——
Serotype 82501.3 (NA to NA)1811.1 (NA to NA)——
Serotype 10A3893.4 (NA to NA)4678.0 (NA to NA)——
Serotype 11A3232.6 (NA to NA)2092.8 (NA to NA)——
Serotype 12F2641.2 (NA to NA)2499.6 (NA to NA)——
Serotype 19A2136.1 (NA to NA)2817.8 (NA to NA)——
Serotype 22F3874.5 (NA to NA)4770.1 (NA to NA)——
Serotype 33F13558.9 (NA to NA)11742.1 (NA to NA)——
Serotype 9N7470.7 (NA to NA)1640.4 (NA to NA)——
Serotype15A5237.2 (NA to NA)1589.0 (NA to NA)——
Serotype 15C4216.2 (NA to NA)2072.3 (NA to NA)——
Serotype 16F4868.2 (NA to NA)846.3 (NA to NA)——
Serotype 17F7764.9 (NA to NA)460.4 (NA to NA)——
Serotype 20A6099.2 (NA to NA)631.1 (NA to NA)——
Serotype 23A3737.2 (NA to NA)461.5 (NA to NA)——
Serotype 23B1082.5 (NA to NA)107.3 (NA to NA)——
Serotype 24F2728.6 (NA to NA)70.5 (NA to NA)——
Serotype 313132.5 (NA to NA)144.4 (NA to NA)——
Serotype 35B8527.8 (NA to NA)1383.0 (NA to NA)——
Statistical analysis
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 1.55 · 95% CI 1.40 to 1.72V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 0.77 · 95% CI 0.68 to 0.88V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 1.06 · 95% CI 0.95 to 1.18V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 1.38 · 95% CI 1.25 to 1.53V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 0.83 · 95% CI 0.75 to 0.93V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 1.54 · 95% CI 1.39 to 1.72V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 1.06 · 95% CI 0.92 to 1.21V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 0.76 · 95% CI 0.69 to 0.84V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 0.81 · 95% CI 0.72 to 0.92V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 1.15 · 95% CI 1.01 to 1.32V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 4.55 · 95% CI 4.12 to 5.04V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 3.30 · 95% CI 2.91 to 3.74V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 2.03 · 95% CI 1.77 to 2.34V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 5.75 · 95% CI 5.16 to 6.41V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 16.86 · 95% CI 14.90 to 19.09V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 9.66 · 95% CI 8.66 to 10.79V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 8.10 · 95% CI 6.86 to 9.55V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 10.09 · 95% CI 8.48 to 12.00V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 38.71 · 95% CI 33.87 to 44.25V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 21.69 · 95% CI 18.68 to 25.18V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · cLDA model · p = <0.001 · Gmt ratio: 6.17 · 95% CI 5.59 to 6.80V116/PCV20
PrimaryPercentage of Participants With ≥4-fold Change From Baseline in Serotype Specific OPA Responses in Cohort 1 Only for the 11 Unique Pneumococcal Serotypes Contained in V116

The percentage of participants with ≥4-fold rise from baseline in serotype specific OPAs for the 11 unique pneumococcal serotypes contained in V116. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Time frame:
Baseline and Day 30 post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥4-fold Change From Baseline in Serotype Specific OPA Responses in Cohort 1 Only for the 11 Unique Pneumococcal Serotypes Contained in V116
Percentage of participantsCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Serotype 9N64.7 (NA to NA)19.9 (NA to NA)——
Serotype 15A66.7 (NA to NA)35.8 (NA to NA)——
Serotype 15C83.4 (NA to NA)74.2 (NA to NA)——
Serotype 16F71.9 (NA to NA)20.8 (NA to NA)——
Serotype 17F75.8 (NA to NA)9.5 (NA to NA)——
Serotype 20A67.3 (NA to NA)9.6 (NA to NA)——
Serotype 23A78.9 (NA to NA)36.8 (NA to NA)——
Serotype 23B85.5 (NA to NA)49.6 (NA to NA)——
Serotype 24F80.5 (NA to NA)6.3 (NA to NA)——
Serotype 3176.5 (NA to NA)17.9 (NA to NA)——
Serotype 35B60.0 (NA to NA)6.8 (NA to NA)——
Statistical analysis
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 44.7 · 95% CI 40.7 to 48.6V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 30.9 · 95% CI 25.8 to 35.8V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 9.2 · 95% CI 5.6 to 12.9V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 51.1 · 95% CI 47.1 to 54.9V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 66.3 · 95% CI 62.8 to 69.6V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 57.7 · 95% CI 54.2 to 61.1V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 42.2 · 95% CI 37.6 to 46.6V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 35.9 · 95% CI 32.1 to 39.6V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 74.2 · 95% CI 71.1 to 77.1V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 58.6 · 95% CI 54.8 to 62.1V116 minus PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Stratified Miettinen & Nurminen · p = <0.001 (1-sided) · Percent difference: 53.2 · 95% CI 49.6 to 56.6V116 minus PCV20
PrimarySerotype Specific OPA GMTs in Participants 18-49 Years and Participants 50-64 Years for the Pneumococcal Serotypes Contained in V116

The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA. GMT values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.

Time frame:
Day 30 post-vaccination
Reported as:
Geometric mean · Titer
Serotype Specific OPA GMTs in Participants 18-49 Years and Participants 50-64 Years for the Pneumococcal Serotypes Contained in V116
TiterV116 18 to 49 Years OldV116 50 to 64 Years OldCohort 1 PCV20Cohort 2 PCV20
Serotype 3308.6 (NA to NA)282.7 (NA to NA)——
Serotype 6A5289.6 (NA to NA)2572.9 (NA to NA)——
Serotype 7F6447.2 (NA to NA)4278.8 (NA to NA)——
Serotype 84516.0 (NA to NA)3004.7 (NA to NA)——
Serotype 9N17283.2 (NA to NA)8791.4 (NA to NA)——
Serotype 10A6808.1 (NA to NA)4382.6 (NA to NA)——
Serotype 11A5871.6 (NA to NA)3785.8 (NA to NA)——
Serotype 12F6150.4 (NA to NA)3561.2 (NA to NA)——
Serotype 15A11319.2 (NA to NA)5901.2 (NA to NA)——
Serotype 15C10194.0 (NA to NA)5708.0 (NA to NA)——
Serotype 16F8877.0 (NA to NA)5720.0 (NA to NA)——
Serotype17F16070.6 (NA to NA)10068.0 (NA to NA)——
Serotype 19A2773.2 (NA to NA)2374.6 (NA to NA)——
Serotype 20A13150.0 (NA to NA)7562.7 (NA to NA)——
Serotype 22F9299.6 (NA to NA)4683.6 (NA to NA)——
Serotype 23A8848.7 (NA to NA)4739.5 (NA to NA)——
Serotype 23B2140.1 (NA to NA)1420.9 (NA to NA)——
Serotype 24F4137.6 (NA to NA)3047.2 (NA to NA)——
Serotype 318005.6 (NA to NA)3820.7 (NA to NA)——
Serotype 33F34805.5 (NA to NA)17607.4 (NA to NA)——
Serotype 35B13933.4 (NA to NA)9053.9 (NA to NA)——
Statistical analysis
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.09 · 95% CI 0.90 to 1.33V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 2.06 · 95% CI 1.61 to 2.62V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.51 · 05% CI 1.23 to 1.84V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.50 · 95% CI 1.26 to 1.79V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.97 · 95% CI 1.59 to 2.43V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.55 · 95% CI 1.26 to 1.92V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.55 · 95% CI 1.26 to 1.91V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.73 · 95% CI 1.37 to 2.17V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.92 · 95% CI 1.55 to 2.37V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.79 · 95% CI 1.36 to 2.35V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.55 · 95% CI 1.26 to 1.91V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.60 · 95% CI 1.26 to 2.02V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.17 · 95% CI 0.97 to 1.40V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.74 · 95% CI 1.39 to 2.18V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.99 · 95% CI 1.58 to 2.49V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.87 · 95% CI 1.43 to 2.44V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.51 · 95% CI 1.11 to 2.04V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.36 · 95% CI 1.10 to 1.67V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 2.10 · 95% CI 1.63 to 2.69V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.98 · 95% CI 1.52 to 2.57V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt ratio: 1.54 · 95% CI 1.26 to 1.87V116 18-49 years/V116 50-64 years
SecondaryPercentage of Participants From Cohort 1 V116 With ≥4-fold Change in OPA Responses for Cross Reactive Pneumococcal Serotypes

The percentage of participants with ≥4-fold rise from baseline was determined for Cohort 1 V116 serotypes 6C and 15B, two serotypes which cross react with PCV20. Point estimate and 95% CI are based on the Clopper-Pearson method. A conclusion of acceptability is based on the lower bound of the 95% CI of the percentages of participants with a ≥4-fold rise from baseline being \> 50 percentage points (one-sided p-value \< 0.025). Per protocol, participants treated with PCV20, and V116 Cohort 2 were not analyzed in this outcome measure.

Time frame:
Baseline and Day 30 post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants From Cohort 1 V116 With ≥4-fold Change in OPA Responses for Cross Reactive Pneumococcal Serotypes
Percentage of participantsCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Serotype 6C49.3 (46.0 to 52.6)———
Serotype 15B64.7 (61.4 to 67.8)———
Statistical analysis
  • Cohort 1 V116 · Clopper-Pearson method. · p = 0.667 (1-sided)
  • Cohort 1 V116 · Clopper-Pearson method. · p = <0.001 (1-sided)
SecondarySerotype Specific OPA GMTs for Cross Reactive Pneumococcal Serotypes in Adults 50 to 64 Years of Age From Cohort 1 and Adults 18 to 49 Years of Age From Cohort 2

The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA for serotypes 6C and 15B which cross react with PCV20. GMT values were estimated from a LDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.

Time frame:
Day 30 post-vaccination
Reported as:
Geometric mean · Titer
Serotype Specific OPA GMTs for Cross Reactive Pneumococcal Serotypes in Adults 50 to 64 Years of Age From Cohort 1 and Adults 18 to 49 Years of Age From Cohort 2
TiterV116 18 to 49 Years OldV116 50 to 64 Years OldCohort 1 PCV20Cohort 2 PCV20
6C2577.2 (NA to NA)1254.7 (NA to NA)——
15B10976.7 (NA to NA)5438.9 (NA to NA)——
Statistical analysis
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · Gmt ratio: 2.05 · 95% CI 1.52 to 2.77V116 18-49 years/V116 50-64 years
  • V116 18 to 49 Years Old vs V116 50 to 64 Years Old · LDA model · p = <0.001 (1-sided) · Gmt: 2.02 · 95% CI 1.57 to 2.60V116 18-49 years/V116 50-64 years
SecondarySerotype Specific Immunoglobulin (IgG) Geometric Mean Concentrations (GMCs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20

The serotype specific IgG GMCs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using pneumococcal electrochemiluminescence (PnECL). GMC values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Time frame:
Day 30 post-vaccination
Reported as:
Geometric mean · μg/mL
Serotype Specific Immunoglobulin (IgG) Geometric Mean Concentrations (GMCs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20
μg/mLCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Serotype 30.78 (NA to NA)0.53 (NA to NA)——
Serotype 6A4.30 (NA to NA)5.45 (NA to NA)——
Serotype 7F6.97 (NA to NA)6.57 (NA to NA)——
Serotype 810.02 (NA to NA)7.00 (NA to NA)——
Serotype 10A11.98 (NA to NA)14.66 (NA to NA)——
Serotype 11A7.20 (NA to NA)5.87 (NA to NA)——
Serotype 12F1.73 (NA to NA)1.57 (NA to NA)——
Serotype 19A8.39 (NA to NA)12.02 (NA to NA)——
Serotype 22F4.39 (NA to NA)5.48 (NA to NA)——
Serotype 33F13.81 (NA to NA)13.02 (NA to NA)——
Serotype 9N7.72 (NA to NA)1.43 (NA to NA)——
Serotype15A13.88 (NA to NA)2.04 (NA to NA)——
Serotype 15C12.39 (NA to NA)5.04 (NA to NA)——
Serotype 16F2.86 (NA to NA)0.33 (NA to NA)——
Serotype 17F14.16 (NA to NA)0.84 (NA to NA)——
Serotype 20A19.03 (NA to NA)1.47 (NA to NA)——
Serotype 23A3.78 (NA to NA)0.59 (NA to NA)——
Serotype 23B5.13 (NA to NA)1.58 (NA to NA)——
Serotype 24F6.87 (NA to NA)0.33 (NA to NA)——
Serotype 313.07 (NA to NA)0.27 (NA to NA)——
Serotype 35B19.98 (NA to NA)1.41 (NA to NA)——
Statistical analysis
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 1.47 · 95% CI 1.35 to 1.60V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 0.79 · 95% CI 0.70 to 0.89V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 1.06 · 95% CI 0.95 to 1.18V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 1.43 · 95% CI 1.29 to 1.59V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 0.82 · 95% CI 0.72 to 0.92V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 1.23 · 95% CI 1.11 to 1.36V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 1.10 · 95% CI 0.96 to 1.26V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 0.70 · 95% CI 0.63 to 0.77V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 0.80 · 95% CI 0.72 to 0.90V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 1.06 · 95% CI 0.95 to 1.18V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 5.41 · 95% CI 4.82 to 6.06V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 6.79 · 95% CI 6.03 to 7.64V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 2.46 · 95% CI 2.17 to 2.79V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 8.75 · 95% CI 7.95 to 9.64V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 16.75 · 95% CI 15.25 to 18.41V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 12.92 · 05% CI 11.81 to 14.13V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 6.42 · 95% CI 5.69 to 7.24V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 3.25 · 95% CI 2.91 to 3.64V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 21.08 · 85% CI 18.97 to 23.43V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 11.31 · 95% CI 10.36 to 12.34V116/PCV20
  • Cohort 1 V116 vs Cohort 1 PCV20 · Gmc ratio: 14.13 · 95% CI 12.97 to 15.40V116/PCV20
SecondaryGeometric Mean Fold Change From Baseline in OPA GMTs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20

The geometric mean fold rise (GMFR) from baseline in serotype specific OPA GMTs for cohort 1 was determined using MOPA. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Time frame:
Baseline and Day 30 post-vaccination
Reported as:
Geometric mean · GMFR
Geometric Mean Fold Change From Baseline in OPA GMTs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20
GMFRCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Serotype 38.4 (7.7 to 9.1)5.4 (5.0 to 5.8)——
Serotype 6A18.1 (16.2 to 20.2)22.6 (20.1 to 25.5)——
Serotype 7F16.5 (14.4 to 18.8)14.7 (12.9 to 16.8)——
Serotype 822.0 (19.3 to 25.0)14.2 (12.5 to 16.2)——
Serotype 10A16.7 (14.8 to 18.9)20.8 (18.3 to 23.8)——
Serotype11A17.4 (15.1 to 20.0)11.6 (10.1 to 13.3)——
Serotype 12F77.4 (68.5 to 87.4)73.5 (64.8 to 83.4)——
Serotype 19A8.6 (7.7 to 9.5)11.0 (9.9 to 12.2)——
Serotype 22F19.1 (16.6 to 22.1)25.5 (21.9 to 29.8)——
Serotype 33F9.9 (8.9 to 11.1)8.5 (7.6 to 9.5)——
Serotype 9N8.9 (8.0 to 9.9)2.0 (1.9 to 2.2)——
Serotype 15A9.4 (8.2 to 10.8)3.1 (2.7 to 3.5)——
Serotype 15C38.0 (33.3 to 43.3)20.3 (17.8 to 23.1)——
Serotype 16F9.5 (8.7 to 10.4)1.9 (1.7 to 2.0)——
Serotype 17F17.3 (15.3 to 19.7)1.2 (1.1 to 1.3)——
Serotype 20A10.3 (9.2 to 11.4)1.2 (1.1 to 1.2)——
Serotype 23A21.8 (19.0 to 25.0)3.1 (2.7 to 3.6)——
Serotype 23B51.4 (45.3 to 58.2)6.1 (5.4 to 6.9)——
Serotype 24F29.0 (25.6 to 32.8)1.1 (1.0 to 1.1)——
Serotype 3128.7 (24.9 to 33.1)1.5 (1.4 to 1.7)——
Serotype 35B7.2 (6.5 to 7.9)1.2 (1.1 to 1.2)——
SecondaryGeometric Mean Fold Change From Baseline in IgG Antibody GMCs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20

The GMFR from baseline in serotype specific IgG antibody GMCs for cohort 1 was determined using PnECL. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Time frame:
Baseline and Day 30 post-vaccination
Reported as:
Geometric mean · GMFR
Geometric Mean Fold Change From Baseline in IgG Antibody GMCs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20
GMFRCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Serotype 35.1 (4.8 to 5.4)3.5 (3.3 to 3.7)——
Serotype 6A12.2 (11.1 to 13.5)15.1 (13.8 to 16.6)——
Serotype 7F12.5 (11.5 to 13.7)12.2 (11.2 to 13.4)——
Serotype 812.6 (11.5 to 13.8)8.8 (8.0 to 9.6)——
Serotype 10A15.4 (14.1 to 16.9)19.2 (17.4 to 21.1)——
Serotype11A8.7 (8.1 to 9.5)7.1 (6.5 to 7.7)——
Serotype 12F13.1 (11.8 to 14.4)12.1 (11.0 to 13.5)——
Serotype 19A5.4 (5.0 to 5.8)7.7 (7.1 to 8.4)——
Serotype 22F12.7 (11.6 to 13.9)16.3 (14.8 to 17.9)——
Serotype 33F9.6 (8.8 to 10.5)9.1 (8.3 to 9.9)——
Serotype 9N15.0 (13.6 to 16.5)2.7 (2.5 to 2.9)——
Serotype 15A22.3 (20.3 to 24.4)3.4 (3.1 to 3.7)——
Serotype 15C19.8 (17.9 to 21.8)8.2 (7.4 to 9.0)——
Serotype 16F13.3 (12.3 to 14.4)1.6 (1.5 to 1.7)——
Serotype 17F19.8 (18.0 to 21.7)1.2 (1.1 to 1.3)——
Serotype 20A11.7 (10.8 to 12.8)0.9 (0.9 to 1.0)——
Serotype 23A17.8 (16.3 to 19.5)2.9 (2.6 to 3.1)——
Serotype 23B12.1 (11.1 to 13.3)3.8 (3.5 to 4.1)——
Serotype 24F21.2 (19.3 to 23.4)1.1 (1.0 to 1.1)——
Serotype 3113.0 (12.0 to 14.0)1.2 (1.2 to 1.3)——
Serotype 35B14.7 (13.6 to 16.0)1.0 (1.0 to 1.1)——
SecondaryPercentage of Participants With ≥4-fold Change From Baseline in IgG Antibody GMCs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20

Percentage of participants with ≥4-fold rise from baseline in serotype specific IgG antibody GMCs for cohort 1 was determined using PnECL. The within-group 95% CIs were based on the exact binomial method proposed by Clopper and Pearson. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Time frame:
Baseline and Day 30 post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥4-fold Change From Baseline in IgG Antibody GMCs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20
Percentage of participantsCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Serotype 356.5 (53.5 to 59.4)41.0 (38.0 to 44.0)——
Serotype 6A73.1 (70.4 to 75.7)79.7 (77.2 to 82.1)——
Serotype 7F76.4 (73.8 to 78.9)75.8 (73.2 to 78.4)——
Serotype 875.8 (73.1 to 78.3)67.8 (64.9 to 70.6)——
Serotype 10A80.3 (77.8 to 82.6)82.0 (79.5 to 84.2)——
Serotype11A71.1 (68.4 to 73.8)62.7 (59.8 to 65.6)——
Serotype 12F74.2 (71.5 to 76.7)71.4 (68.6 to 74.1)——
Serotype 19A55.6 (52.6 to 58.5)65.0 (62.0 to 67.8)——
Serotype 22F76.8 (74.2 to 79.3)78.5 (76.0 to 81.0)——
Serotype 33F71.6 (68.8 to 74.2)66.7 (63.8 to 69.6)——
Serotype 9N77.9 (75.3 to 80.3)29.4 (26.7 to 32.2)——
Serotype 15A85.7 (83.5 to 87.8)37.7 (34.8 to 40.7)——
Serotype 15C81.4 (78.9 to 83.6)63.2 (60.2 to 66.1)——
Serotype 16F81.4 (78.9 to 83.6)11.8 (10.0 to 13.9)——
Serotype 17F84.5 (82.2 to 86.6)4.3 (3.1 to 5.7)——
Serotype 20A74.7 (72.1 to 77.3)1.3 (0.7 to 2.2)——
Serotype 23A85.5 (83.3 to 87.6)29.4 (26.7 to 32.2)——
Serotype 23B76.1 (73.4 to 78.6)42.2 (39.3 to 45.2)——
Serotype 24F84.0 (81.7 to 86.1)2.3 (1.5 to 3.4)——
Serotype 3181.1 (78.6 to 83.4)3.9 (2.8 to 5.2)——
Serotype 35B83.1 (80.8 to 85.3)3.3 (2.3 to 4.5)——
SecondaryPercentage of Participants With ≥4-fold Change From Baseline in OPA GMTs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20

Percentage of participants with ≥4-fold rise from baseline in OPA GMTs in Cohort 1 was determined using MOPA. The within-group 95% CIs were based on the exact binomial method proposed by Clopper and Pearson. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Time frame:
Baseline and Day 30 post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥4-fold Change From Baseline in OPA GMTs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20
Percentage of participantsCohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20
Serotype 371.3 (68.4 to 74.2)59.1 (55.9 to 62.3)——
Serotype 6A76.8 (74.0 to 79.5)79.9 (77.2 to 82.4)——
Serotype 7F71.0 (68.1 to 73.9)65.9 (62.8 to 68.9)——
Serotype 875.8 (73.0 to 78.4)67.4 (64.3 to 70.3)——
Serotype 10A71.9 (69.0 to 74.6)74.1 (71.3 to 76.9)——
Serotype11A70.0 (66.9 to 73.0)61.5 (58.2 to 64.7)——
Serotype 12F89.0 (87.0 to 90.9)87.1 (84.9 to 89.1)——
Serotype 19A64.4 (61.3 to 67.3)70.2 (67.2 to 73.0)——
Serotype 22F70.5 (67.5 to 73.4)74.4 (71.5 to 77.2)——
Serotype 33F67.7 (64.6 to 70.7)61.5 (58.3 to 64.6)——
Serotype 9N64.7 (61.5 to 67.8)19.9 (17.5 to 22.6)——
Serotype 15A66.7 (63.0 to 70.2)35.8 (32.3 to 39.5)——
Serotype 15C83.4 (80.9 to 85.7)74.2 (71.2 to 76.9)——
Serotype 16F71.9 (68.8 to 74.8)20.8 (18.3 to 23.5)——
Serotype 17F75.8 (72.7 to 78.6)9.5 (7.7 to 11.5)——
Serotype 20A67.3 (64.3 to 70.2)9.6 (7.8 to 11.6)——
Serotype 23A78.9 (75.8 to 81.7)36.8 (33.3 to 40.4)——
Serotype 23B85.5 (83.2 to 87.6)49.6 (46.4 to 52.7)——
Serotype 24F80.5 (77.8 to 83.0)6.3 (4.8 to 8.1)——
Serotype 3176.5 (73.6 to 79.3)17.9 (15.5 to 20.5)——
Serotype 35B60.0 (56.7 to 63.2)6.8 (5.3 to 8.5)——

Adverse events

Collected over All-cause mortality (ACM): Randomization up to 194 days post-vaccination. Serous adverse events (SAEs): Treatment (Day 1) up to 194 days post-vaccination. Non-serious AEs (NSAEs): Treatment (Day 1) up to 30 days post-vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: V1164/1,179 (0.3%)19/1,177 (1.6%)615/1,177 (52.3%)
Cohort 1: PCV202/1,179 (0.2%)24/1,175 (2%)722/1,175 (61.4%)
Cohort 2: V1160/201 (0%)1/200 (0.5%)161/200 (80.5%)
Cohort 2: PCV200/100 (0%)3/100 (3%)78/100 (78%)
Unplanned Participants0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventCohort 1: V116Cohort 1: PCV20Cohort 2: V116Cohort 2: PCV20Unplanned Participants
Jejunal perforationGastrointestinal disorders0/11770/11750/2001/1000/2
CellulitisInfections and infestations0/11770/11750/2001/1000/2
Lower limb fractureInjury, poisoning and procedural complications0/11770/11750/2001/1000/2
Tooth abscessInfections and infestations0/11770/11751/2000/1000/2
Myocardial infarctionCardiac disorders1/11774/11750/2000/1000/2
SepsisInfections and infestations2/11770/11750/2000/1000/2
Cerebrovascular accidentNervous system disorders2/11770/11750/2000/1000/2
Cardiac arrestCardiac disorders1/11771/11750/2000/1000/2
Coronary artery embolismCardiac disorders0/11771/11750/2000/1000/2
VertigoEar and labyrinth disorders0/11771/11750/2000/1000/2
Most frequent other events
Most frequent other events
EventCohort 1: V116Cohort 1: PCV20Cohort 2: V116Cohort 2: PCV20Unplanned Participants
Injection site painGeneral disorders471/1177608/1175143/20074/1000/2
FatigueGeneral disorders240/1177235/117581/20034/1000/2
HeadacheNervous system disorders162/1177174/117559/20026/1000/2
MyalgiaMusculoskeletal and connective tissue disorders75/117782/117533/20014/1000/2
Injection site erythemaGeneral disorders82/117786/117532/20013/1000/2
Injection site swellingGeneral disorders79/1177103/117528/20014/1000/2

Baseline characteristics

All vaccinated participants. Includes two participants from Cohort 1 who had unplanned vaccinations with both V116 and PCV20

Age, Continuous
Age, Continuous(Years)Cohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20Total
Mean63.9 ± 8.363.9 ± 8.335.2 ± 9.034.6 ± 8.760.7 ± 12.4
Age, Customized
Age, Customized(Participants)Cohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20Total
18 to 49 years00200100300
50 to 64 years589587001176
65 to 74 years46446400928
75 to 84 years11211300225
≥85 years14130027
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20Total
Female687670137641558
Male49250763361098
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20Total
Hispanic or Latino2592425824583
Not Hispanic or Latino909922141762048
Unknown or Not Reported11131025
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 V116Cohort 1 PCV20Cohort 2 V116Cohort 2 PCV20Total
American Indian or Alaska Native44019
Asian1481683815369
Native Hawaiian or Other Pacific Islander17161236
Black or African American1161151314258
White867844139621912
More than one race26309671
Unknown or Not Reported10001
08

Study locations

112 sites
  • Central Research Associates ( Site 0067)
    Birmingham, Alabama 35205, United States
  • Lenzmeier Family Medicine/CCT Research ( Site 0006)
    Glendale, Arizona 85308, United States
  • Desert Clinical Research/ CCT Research ( Site 0040)
    Mesa, Arizona 85213, United States
  • Foothills Research Center/ CCT Research ( Site 0021)
    Phoenix, Arizona 85044, United States
  • Fiel Family and Sports Medicine, PC/CCT Research ( Site 0003)
    Tempe, Arizona 85283, United States
  • Baptist Health Center For Clinical Research ( Site 0019)
    Little Rock, Arkansas 72205, United States
  • Southland Clinical Research Center-Research ( Site 0054)
    Fountain Valley, California 92708, United States
  • Sunwise Clinical Research ( Site 0024)
    Lafayette, California 94549, United States
  • Chemidox Clinical Trials ( Site 0048)
    Lancaster, California 93534, United States
  • Paradigm Clinical Research Centers, Inc ( Site 0018)
    Redding, California 96001, United States
  • Peninsula Research Associates ( Site 0079)
    Rolling Hills Estates, California 90274, United States
  • Acclaim Clinical Research ( Site 0083)
    San Diego, California 92120, United States
  • Millennium Clinical Trials ( Site 0013)
    Simi Valley, California 93065, United States
  • Lynn Institute of Denver ( Site 0012)
    Aurora, Colorado 80012, United States
  • Paradigm Clinical Research Centers, Inc ( Site 0027)
    Wheat Ridge, Colorado 80033, United States
  • JEM Research Institute ( Site 0072)
    Atlantis, Florida 33462, United States
  • Alliance for Multispecialty Research, LLC ( Site 0015)
    Coral Gables, Florida 33134, United States
  • Hillcrest Medical Research ( Site 0049)
    DeLand, Florida 32720, United States
  • East Coast Institute for Research, LLC ( Site 0070)
    Jacksonville, Florida 32204, United States
  • East Coast Institute for Research ( Site 0071)
    Lake City, Florida 32055, United States
  • L&C Professional Medical Research Institute ( Site 0025)
    Miami, Florida 33144, United States
  • Advanced Medical Research Institute ( Site 0014)
    Miami, Florida 33174, United States
  • Headlands Research Orlando ( Site 0031)
    Orlando, Florida 32819, United States
  • Genesis Clinical Research, LLC ( Site 0016)
    Tampa, Florida 33603, United States
  • Clinical Research Trials of Florida ( Site 0007)
    Tampa, Florida 33607, United States
  • Palm Beach Research Center ( Site 0060)
    West Palm Beach, Florida 33409, United States
  • Clinical Research Prime ( Site 0010)
    Idaho Falls, Idaho 83404, United States
  • Solaris Clinical Research ( Site 0008)
    Meridian, Idaho 83646, United States
  • Versailles Family Medicine / CCT Research ( Site 0063)
    Versailles, Kentucky 40383, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0038)
    Troy, Michigan 48098, United States
  • Alliance for Multispecialty Research, LLC ( Site 0026)
    Kansas City, Missouri 64114, United States
  • Skyline Medical Center/CCT Research ( Site 0028)
    Elkhorn, Nebraska 68022, United States
  • Methodist Physicians Clinic/CCT Research ( Site 0058)
    Fremont, Nebraska 68025, United States
  • Meridian Clinical Research, LLC ( Site 0045)
    Norfolk, Nebraska 68701, United States
  • Healor Primary Care / CCT Research ( Site 0056)
    Las Vegas, Nevada 89102, United States
  • Excel Clinical Research, LLC ( Site 0077)
    Las Vegas, Nevada 89109, United States
  • Santa Rosa Medical Centers of Nevada / CCT Research ( Site 0029)
    Las Vegas, Nevada 89119, United States
  • Smith Allergy & Asthma Specialists-Corning Center for Clinical Research ( Site 0032)
    Horseheads, New York 14845, United States
  • Aventiv Research Inc ( Site 0044)
    Columbus, Ohio 43213, United States
  • Advanced Medical Research ( Site 0002)
    Maumee, Ohio 43537, United States
  • Lynn Institute of Norman ( Site 0001)
    Norman, Oklahoma 73072, United States
  • Lynn Health Science Institute ( Site 0005)
    Oklahoma City, Oklahoma 73112, United States
  • Lynn Institute of Tulsa ( Site 0084)
    Tulsa, Oklahoma 74135, United States
  • Summit Headlands ( Site 0047)
    Portland, Oregon 97210, United States
  • Velocity Clinical Research, Greenville ( Site 0043)
    Greenville, South Carolina 29615, United States
  • Trial Management Associates ( Site 0089)
    Myrtle Beach, South Carolina 29572, United States
  • Tekton Research, Inc. ( Site 0053)
    Austin, Texas 78745, United States
  • WR-Global Medical Research, LLC ( Site 0065)
    Dallas, Texas 75224, United States
  • Elixir Research Group - W Houston ( Site 0068)
    Houston, Texas 77077, United States
  • Epic Clinical Research ( Site 0082)
    Lewisville, Texas 75067, United States
  • DCOL Center for Clinical Research ( Site 0051)
    Longview, Texas 75605, United States
  • Research Your Health ( Site 0042)
    Plano, Texas 75093, United States
  • IMA Clinical Research San Antonio ( Site 0009)
    San Antonio, Texas 78229, United States
  • VIP Trials ( Site 0086)
    San Antonio, Texas 78230, United States
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research-DM Clinical Research ( Site 0036)
    Tomball, Texas 77375, United States
  • Olympus Family Medicine/CCT Research ( Site 0074)
    Holladay, Utah 84117, United States
  • South Ogden Family Medicine/ CCT Research ( Site 0022)
    Ogden, Utah 84405, United States
  • Charlottesville Medical Research ( Site 0034)
    Charlottesville, Virginia 22911, United States
  • Health Research of Hampton Roads, Inc. ( Site 0004)
    Newport News, Virginia 23606, United States
  • MultiCare Rockwood Cheney Clinic ( Site 0037)
    Spokane, Washington 99204, United States
  • Paratus Clinical Research Canberra ( Site 3000)
    Bruce, Australian Capital Territory 2617, Australia
  • Emeritus Research ( Site 3004)
    Botany, New South Wales 2019, Australia
  • Paratus Clinical Research Central Coast ( Site 3001)
    Kanwal, New South Wales 2259, Australia
  • Westmead Hospital ( Site 3005)
    Westmead, New South Wales 2145, Australia
  • Emeritus Research ( Site 3003)
    Camberwell, Victoria 3124, Australia
  • Anima Diepenbeek ( Site 1003)
    Diepenbeek, Limburg 3590, Belgium
  • Private Practice - Dr. Martinot Jean-Benoit ( Site 1001)
    Erpent, Namur 5101, Belgium
  • Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 0504)
    Temuco, Araucania 4781151, Chile
  • Universidad San Sebastian - Providencia ( Site 0514)
    Providencia, Region M. De Santiago 7500000, Chile
  • Espacio Eme ( Site 0509)
    Santiago, Region M. De Santiago 7770086, Chile
  • Centro de Investigacion Clinicadela Universidad Catolica ( Site 0503)
    Santiago, Region M. De Santiago 8330034, Chile
  • InfektioResearch ( Site 1203)
    Frankfurt, Hessen 60596, Germany
  • Medizentrum Essen Borbeck ( Site 1200)
    Essen, Nordrhein-Westfalen 45355, Germany
  • Universitaetsklinikum Koeln ( Site 1206)
    Köln, Nordrhein-Westfalen 50937, Germany
  • Novopraxis Berlin GbR ( Site 1201)
    Berlin, 10117, Germany
  • Universitaetsklinikum Hamburg-Eppendorf-Infektiologie ( Site 1202)
    Hamburg, 20246, Germany
  • Hamburger Institut fuer Therapieforschung GmbH ( Site 1204)
    Hamburg, 20354, Germany
  • Gachon University Gil Medical Center ( Site 3205)
    Namdong-gu, Incheon 21565, Korea, Republic of
  • Korea University Ansan Hospital ( Site 3201)
    Ansan-si, Kyonggi-do 15355, Korea, Republic of
  • The Catholic University Of Korea St. Vincent's Hospital-Internal Medicine ( Site 3206)
    Suwon-si, Kyonggi-do 16247, Korea, Republic of
  • Ajou University Hospital-Department of Infectious Diseases ( Site 3209)
    Suwon-si, Kyonggi-do 16499, Korea, Republic of
  • Kyungpook National University Chilgok Hospital-Division of Infectious Diseases ( Site 3207)
    Deagu, Taegu-Kwangyokshi 41404, Korea, Republic of
  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 3202)
    Seoul, 03312, Korea, Republic of
  • Severance Hospital, Yonsei University Health System-Division of Infectious Diseases ( Site 3210)
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center ( Site 3211)
    Seoul, 06351, Korea, Republic of
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 3203)
    Seoul, 06591, Korea, Republic of
  • Hallym University Kangnam Sacred Heart Hospital-Internal Medicine ( Site 3204)
    Seoul, 07441, Korea, Republic of
  • Ewha Womans University Mokdong Hospital-Infectious Diseases ( Site 3208)
    Seoul, Korea, Republic of
  • Korea University Guro Hospital ( Site 3200)
    Seoul, Korea, Republic of
  • Lakeland Clinical Trials ( Site 3102)
    Rotorua, Bay Of Plenty 3010, New Zealand
  • P3 Research - Tauranga ( Site 3100)
    Tauranga, Bay Of Plenty 3110, New Zealand
  • Southern Clinical Trials Ltd ( Site 3104)
    Christchurch, Canterbury 8013, New Zealand
  • Southern Clinical Trials Waitemata Ltd ( Site 3105)
    Auckland, 0626, New Zealand
  • P3 Research - Wellington ( Site 3101)
    Wellington, 6021, New Zealand
  • Cooperativa De Facultad Medica Sanacoop-Instituto Sanacoop ( Site 0601)
    Bayamon, 00961, Puerto Rico
  • San Juan Bautista School of Medicine - Clinical Research Unit ( Site 0606)
    Caguas, 00725, Puerto Rico
  • Clinical Research Investigator Group ( Site 0611)
    Canovanas, 00729, Puerto Rico
  • Ponce School Of Medicine Caimed Center ( Site 0602)
    Ponce, 00716, Puerto Rico
  • Clinical Research Puerto Rico ( Site 0600)
    San Juan, 00909, Puerto Rico
  • ProbarE ( Site 1400)
    Lund, Skane Lan 222 22, Sweden

Showing the first 100 of 112 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Platt HL, Bruno C, Buntinx E, Pelayo E, Garcia-Huidobro D, Barranco-Santana EA, Sjoberg F, Song JY, Grijalva CG, Orenstein WA, Morgan L, Fernsler D, Xu W, Waleed M, Li J, Buchwald UK; STRIDE-3 Study Group. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial. Lancet Infect Dis. 2024 Oct;24(10):1141-1150. doi: 10.1016/S1473-3099(24)00344-X. Epub 2024 Jul 1. PubMed 38964361 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2023, 10 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 10 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2022
First posted
Jun 21, 2022
StartActual
Jul 13, 2022
Primary completionActual
May 18, 2023
CompletionActual
May 18, 2023
Results first posted
Jun 10, 2024
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05425732
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Jul 13, 2022
Primary completion
May 18, 2023
Completion
May 18, 2023
Results posted
Jun 10, 2024
Last update
Oct 26, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion